BamSEC and AlphaSense Join Forces
Learn More

Theravance Biopharma Inc.

NASDAQ: TBPH    
Share price (1/8/25): $9.05    
Market cap (1/8/25): $445 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 22 pages Employment Contract of Indefinite Duration
12/34/56
EX-10.2
from 10-Q 7 pages Separation Agreement and Release of Claims
12/34/56
EX-10.1
from 10-Q 4 pages Theravance Biopharma Inc. Amended and Restated 2013 Equity Incentive Plan Restricted Share Purchase Agreement
12/34/56
EX-10.39
from 10-K 3 pages June 12, 2018 Revised Offer Rhonda F. Farnum [Address] Dear Rhonda
12/34/56
EX-10.1
from 8-K 27 pages Cooperation Agreement
12/34/56
EX-10.3
from 10-Q 7 pages Theravance Biopharma, Inc. 2013 Equity Incentive Plan Notice of Restricted Share Unit Award
12/34/56
EX-10.2
from 10-Q 2 pages [Theravance Biopharma Company Logo] ​ June 16, 2014 ​ Aziz Sawaf ​ Dear Aziz: ​
12/34/56
EX-10.1
from 10-Q 5 pages ​ [Theravance Biopharma Company Logo] ​ May 12, 2014 ​ Brett Grimaud ​ Dear Brett: ​
12/34/56
EX-10.1
from 8-K 17 pages Amended and Restated 2013 Equity Incentive Plan Theravance Biopharma, Inc. 2013 Equity Incentive Plan (Originally Adopted Effective October 22, 2013, Amended & Restated Effective February 14, 2023) 1
12/34/56
EX-10.77
from 10-K 8 pages Separation Agreement and Release of Claims
12/34/56
EX-10.72
from 10-K 14 pages To the Members and the Board of Directors of Theravance Respiratory Company, LLC Opinion on the Financial Statements
12/34/56
EX-10.4
from 10-Q 2 pages First Amendment to the Theravance Biopharma, Inc. Change in Control Severance Plan ​
12/34/56
EX-10.2
from 8-K 8 pages Release Agreement
12/34/56
EX-10.1
from 8-K 43 pages Master Consent
12/34/56
EX-10.72
from 10-K 14 pages To the Members and the Board of Directors of Theravance Respiratory Company, LLC Opinion on the Financial Statements
12/34/56
EX-10.71
from 10-K 9 pages Settlement Agreement
12/34/56
EX-10.70
from 10-K 5 pages Consulting Agreement
12/34/56
EX-10.69
from 10-K 8 pages Separation Agreement and Release of Claims
12/34/56
EX-10.60
from 10-K 105 pages License and Collaboration Agreement by and Between Theravance Biopharma Ireland Limited, and Janssen Biotech, Inc. Dated as of February 5, 2018
12/34/56
EX-10.51
from 10-K 95 pages Development and Commercialization Agreement
12/34/56